Release date: October 9, 2006
Review date: October 24, 2007
Available for credit through: October 31, 2008
Program Description
Neutropenia is the major dose-limiting toxicity associated with cancer chemotherapy and febrile neutropenia is associated with considerable morbidity, mortality, and cost. Colony Stimulating Factors, or CSFs, are used to reduce the severity and duration of chemotherapy-induced neutropenia and diminish the risk of febrile neutropenia and infection for patients receiving chemotherapy. The risk of neutropenia varies depending on the agent used and dose delivered. Predictive factors of febrile neutropenia have been identified for several types of malignancies. Identification of these risk factors when chemotherapy is planned can support the appropriate use of CSFs to reduce the risk of febrile neutropenia for patients.
As oncology nurses often have the most time with patients and are the distal provider to the administration of chemotherapy, the development of educational offerings for this group will increase the dissemination of research findings and professional guidelines. Oncology nurses are particularly interested in evidence-based guidelines, standing orders, and pre-existing protocols to streamline practice and improve patient outcomes. Our expert panel of the nation's leading oncology nurse specialists will discuss process improvement and guideline development for appropriate use of myeloid growth factors in the hospital setting; as well as primary prophylaxis standing orders in the clinic setting for prevention of febrile neutropenia.
Target Audience
This activity is intended for Oncology Nurses, Advanced Practice Nurses, Nurse Practitioners, Physician Assistants, and Certified Case Managers caring for patients receiving chemotherapy.
Educational Objectives
At the conclusion of this activity, participants will be able to:
Summarize recent clinical data and guidelines
Identification of patients at risk for adverse outcomes related to CIN, and
Evidence-based management strategy of patients based on risk
Apply the findings from these data and guidelines in clinical case studies
Discuss process improvement and guideline development in the hospital setting; and primary prophylaxis standing orders in the clinic setting with a focus on improved patient outcomes
Accreditation
ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
ArcMesa Educators designates this educational activity for a maximum of 1 AMA PRA Category 1 creditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ArcMesa Educators is an approved provider of continuing education in nursing by the ASNA, an accredited approver by the ANCC Commission on Accreditation. Participants are entitled to receive 1 contact hour upon successful completion of the activity.
Faculty Disclosure Declarations
Christopher R. Friese, RN, PhD, AOCN® – Advisor/Speakers Bureau/Honoraria – Amgen
Joan M. Giblin, MSN, APRN-BC, AOCN® – Nothing to disclose
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of Amgen, any other manufacturer of pharmaceuticals, or ArcMesa Educators.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Printer settings may vary. Please use landscape layout option.
